CHICAGO (REUTERS) - Pfizer's smoking cessation drug, Chantix, carries too many risks and should only be tried when other treatments fail, US researchers said on Wednesday.
Chantix was eight times more likely to be linked with a reported case of suicidal behaviour or depression than other nicotine replacement products, such as the nicotine patch, they said.
The findings, which Pfizer said were flawed, contradicted two studies released last month by the US Food and Drug Administration that showed Chantix (sold as Champix outside the United States) did not increase the risk of being hospitalised for psychiatric problems such as depression.
The agency at the time acknowledged those studies were flawed because they were too small to identify rare events and captured only cases severe enough to land people in the hospital.
Thursday, November 03, 2011
New US study says Chantix raises suicide risks